Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:671453rdf:typepubmed:Citationlld:pubmed
pubmed-article:671453lifeskim:mentionsumls-concept:C0023418lld:lifeskim
pubmed-article:671453lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:671453lifeskim:mentionsumls-concept:C0887819lld:lifeskim
pubmed-article:671453pubmed:issue6lld:pubmed
pubmed-article:671453pubmed:dateCreated1978-9-15lld:pubmed
pubmed-article:671453pubmed:abstractTextQuantitative structure-activity relationships (QSAR) have been formulated for phenyl-, pyrazolyl-, and imidazolyltriazenes acting L1210 leukemia in mice. All three sets of congeners have the same ideal lipophilicity (log Po approximately 1). Electron releasing substituents increase potency; ortho substitution decreases activity. The synthesis of a number of new triazenes and some of their partition coefficients are reported.lld:pubmed
pubmed-article:671453pubmed:languageenglld:pubmed
pubmed-article:671453pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:671453pubmed:citationSubsetIMlld:pubmed
pubmed-article:671453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:671453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:671453pubmed:statusMEDLINElld:pubmed
pubmed-article:671453pubmed:monthJunlld:pubmed
pubmed-article:671453pubmed:issn0022-2623lld:pubmed
pubmed-article:671453pubmed:authorpubmed-author:SmithR NRNlld:pubmed
pubmed-article:671453pubmed:authorpubmed-author:KimK HKHlld:pubmed
pubmed-article:671453pubmed:authorpubmed-author:QuinnF RFRlld:pubmed
pubmed-article:671453pubmed:authorpubmed-author:HanschCClld:pubmed
pubmed-article:671453pubmed:authorpubmed-author:SchmidtC LCLlld:pubmed
pubmed-article:671453pubmed:authorpubmed-author:HathewayG JGJlld:pubmed
pubmed-article:671453pubmed:authorpubmed-author:MilsteinS RSRlld:pubmed
pubmed-article:671453pubmed:issnTypePrintlld:pubmed
pubmed-article:671453pubmed:volume21lld:pubmed
pubmed-article:671453pubmed:ownerNLMlld:pubmed
pubmed-article:671453pubmed:authorsCompleteYlld:pubmed
pubmed-article:671453pubmed:pagination563-74lld:pubmed
pubmed-article:671453pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-A...lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-M...lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-K...lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-T...lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-I...lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-A...lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-L...lld:pubmed
pubmed-article:671453pubmed:meshHeadingpubmed-meshheading:671453-S...lld:pubmed
pubmed-article:671453pubmed:year1978lld:pubmed
pubmed-article:671453pubmed:articleTitleAntitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.lld:pubmed
pubmed-article:671453pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:671453pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:671453lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:671453lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:671453lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:671453lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:671453lld:pubmed